• Novo Nordisk is trading 4.7% down today at $44.88 following the release of its Q2 2026 financial results and updated outlook today, August 4, 2026.
  • While the company raised its full-year 2026 adjusted sales and operating profit outlook, Q2 reported operating profit decreased by 16% at constant exchange rates, impacted by DKK 6.3 billion in non-cash impairment charges related to pipeline assets, including the recently failed ZEUS trial.
  • The market continues to focus on the commercial performance of the company's obesity treatments ahead of the full Q2 earnings call scheduled for August 5, 2026.